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Neuroprotective strategies that limit secondary tissue
loss and/or improve functional outcomes have been
identified in multiple animal models of ischemic,
hemorrhagic, traumatic and nontraumatic cerebral
lesions. However, use of these potential interventions
in human randomized controlled studies has generally
given disappointing results. In this paper, we summarize
the current status in terms of neuroprotective strategies,
both in the immediate and later stages of acute brain
injury in adults. We also review potential new strategies
and highlight areas for future research.has been largely disappointing. Box 1 summarizes import-Introduction
Acute brain injury, whatever its cause, is associated with
considerable short-term and long-term morbidity and
mortality. In the USA it is estimated that 52,000 fatalities
arise as a result of traumatic brain injury (TBI) every
year, and approximately 5.3 million people live with TBI-
related disabilities [1]. These figures are similar in the
European Union, where an estimated 7.7 million people
have TBI-related disabilities [2]. Accurate data from
emerging economies, where TBI is increasing due to
greater motorization, are lacking, but are likely to be
similar or worse [3]. Stroke is the second leading cause
of death and the third leading cause of disability-adjusted
life-years worldwide, and its global burden is increasing
[4]. Other ischemic and hemorrhagic lesions to the brain,
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unless otherwise stated.after cardiac arrest, are also associated with high mor-
tality and devastating sequelae [5,6].
Following the primary cerebral insult, a cascade of
events amplifies the initial damage regardless of the eti-
ology of the precipitating event. Secondary biochemical
changes contribute to subsequent tissue damage with
associated neuronal cell death. The time course over
which these effects occur may be longer than assumed
previously, potentially providing a wider time window for
interventions. Neuroprotective agents that can limit sec-
ondary tissue loss and/or improve behavioral outcomes
have been identified in multiple animal models of acute
brain injury. However, translation to the clinical setting
ant methodological issues in animal studies that have
often not been adequately addressed before clinical trial.
Given the severity and long-term consequences and
costs of brain damage from many different etiologies,
strategies for neuroprotection are of obvious importance.
In this review, based on expert opinion and nonsystem-
atic literature review, we provide an up-to-date summary
of the current evidence for strategies to protect the brain
from secondary insults and highlight areas for future
experimental and clinical research. We have focused on
general concepts in selected pathophysiological events, be-
cause complete coverage of all acute brain injuries is not
feasible in one manuscript, and we restricted our analysis
to adult patients.Existing therapeutic modalities for
neuroprotection
Reperfusion strategies in ischemic stroke
Early reperfusion therapy to restore blood flow to salvage-
able ischemic brain can prevent cell death and facilitate
neurological recovery. Reperfusion may be accomplished
through administration of intravenous thrombolytic agents,ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Box 1. Important aspects that need to be considered
to improve preclinical studies in neuroprotection
1. Effects evaluated across injury severities.
2. Randomization and blinding procedures used.
3. Demonstrated effectiveness of structurally different drugs
and genetic manipulation to confirm mechanism.
4. Evaluation of clinically relevant therapeutic window.
5. Examination of late functional outcomes as well as
histological ones.
6. Elucidated pharmacokinetics and brain concentrations of
drug associated with treatment efficacy.
7. Evaluation of treatment across sex and age spectrum.
8. Comparison of effects in multiple models and species.
9. Replication of therapeutic effect across laboratories.
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omy, ultrasound-enhanced thrombolysis and various
combinations of these approaches. Alternative or adjunct
approaches include enhanced oxygen delivery, hemodilu-
tion and systemic central hemodynamic augmentation
therapy [7]. Risks associated with reperfusion therapies,
apart from failure to reperfuse, include intracerebral
hemorrhage (ICH), ischemia–reperfusion injury and ca-
theterization complications. A large-scale randomized trial
indicated that intravenous recombinant tissue plasmi-
nogen activator (alteplase) administered within 3 hours of
ischemic stroke onset was associated with significantly im-
proved functional outcomes when compared with placebo,
but with an increased risk of ICH [8]. More recent
data indicated that intravenous alteplase was benefi-
cial when given within 4.5 hours of onset in nondiabetic
patients <80 years old without massive strokes [9].
Despite increased risks of ICH and early death, a
Cochrane review of 27 controlled trials of thrombolytic
agents given within 6 hours of acute ischemic stroke
onset indicated improved survival and neurological
outcome at 3 to 6 months; benefits were greater in
patients treated within 3 hours [10]. The evidence offered
by these papers has been incorporated into guidelines,
which recommend early intravenous thrombolysis [11].
There is ongoing interest in selectively treating pa-
tients who have a mismatch between brain tissue that is
hypoperfused on neuroimaging but deemed salvageable
and tissue that has or is predicted to infarct, because
studies have demonstrated that patients who have a
mismatch are more likely to have a favorable outcome
following reperfusion than those who do not [12,13].
Restoring perfusion by selectively targeting the oc-
cluded artery via intra-arterial thrombolysis or mechanicalthromboembolectomy may also be beneficial in patients
with ischemic stroke symptom onset of >4.5 hours or those
for whom systemic intravenous thrombolysis is contrain-
dicated [11,14]. Recent data on intra-arterial strategies as
an alternative or supplement to intravenous thrombolysis
in tissue plasminogen activator-eligible patients have been
mixed [13,15-17], but they indicate potential benefit in
stroke with proximal large vessel occlusions.
Prevention of secondary insults after traumatic brain injury
Various insults can aggravate the initial traumatic brain
damage and preventing or minimizing such insults rep-
resents a form of brain protection. For example, early
removal of large intracranial hematomas that compress
the brain is a key intervention. However, published
supportive evidence is lacking and randomized trials
comparing early versus delayed surgery would probably
encounter ethical challenges [18]. Nevertheless, in the case
of epidural hematoma management, shortening the time
from trauma to surgery was associated with improved out-
comes in a prospective cohort study [19]. Decompressive
craniectomy is sometimes used in TBI patients with raised
intracranial pressure (ICP) not responding to first-tier in-
tensive care and neurosurgical therapies. A randomized
controlled trial, however, found that those randomized to
decompressive craniectomy had decreased ICP and length
of ICU stay but more unfavorable outcomes as deter-
mined by the Extended Glasgow Outcome Scale at
6 months after injury [20].
The deleterious effects of hypoxia and arterial hypo-
tension in the early phases after TBI have been identified
in several analyses. Data from the US Traumatic Coma
Data Bank collected from 1983 to 1988 showed that
among 717 TBI admissions, hypoxia (defined as arterial
oxygen tension <60 mmHg, cyanosis or apnea) and/or
hypotension (defined as systolic pressure <90 mmHg)
were identified in 45% of cases and were independ-
ently associated with significant increases in morbidity
and mortality [21]. Similar findings were reported in
the International Mission on Prognosis and Analysis
of randomized Controlled Trials (IMPACT) in TBI study
[22] and confirmed in other recent reports [23,24]. Cor-
rection of arterial hypotension and hypoxia is therefore
mandatory [25].
There is no evidence to indicate the superiority of new
approaches, such as hypertonic fluids, over conventional
isotonic saline to correct hypotension [26]. The role of
prehospital intubation in neuroprotection has been
questioned in the past [27], but more recent studies sug-
gest it may be associated with more favorable outcomes,
as evaluated by the Extended Glasgow Outcome Scale
score at 6 months [28]. Increased ICP, reduced cerebral
perfusion, seizures, and so forth, represent further sec-
ondary insults to the traumatized brain; early detection
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outcomes [29].
Autoregulation and neuroprotection
Cerebrovascular autoregulation is the ability of the brain
to maintain a constant cerebral blood flow (CBF) through
a range of cerebral perfusion pressures (CPP) [30]. Several
dynamic pressure reactivity indices have been proposed
for monitoring cerebrovascular autoregulation in real time
at the bedside, by calculating the correlation between the
arterial blood pressure and continuous measures of CBF
or cerebral blood volume [30]. When this correlation is
negative or close to zero, autoregulation is assumed to be
present (pressure active); when it is positive, autoregula-
tion is considered to be absent (pressure passive). ICP,
transcranial Doppler, brain tissue oxygenation and near-
infrared spectroscopy have all been used as estimates of
global CBF/cerebral blood volume. Accordingly, the CPP
range at which autoregulation is best preserved (optimal
CPP) can be estimated. However, whether a strategy based
on these measurements might be used to improve out-
comes has yet to be demonstrated [31].
Hemoglobin management for neuroprotection
Anemia is common among patients with severe brain
injury and is associated with poor outcomes in TBI,
aneurysmal subarachnoid hemorrhage (SAH), ICH and
acute ischemic stroke [32,33]. In the absence of serious
cardiac disease, a restrictive red blood cell transfusion
strategy (for example, trigger hemoglobin (Hb) 7 g/dl) is
usually recommended in critically ill patients [34]. In
severe brain injury, however, compromised brain tissue
oxygenation may occur at higher Hb levels than in other
ICU patients [35,36].
In a recent randomized clinical trial in 200 patients
with closed head injury, erythropoietin was compared
with placebo in patients with transfusion thresholds of
7 g/dl versus 10 g/dl [37]. There were no statistically sig-
nificant differences in 6-month neurological outcomes
between the two transfusion groups, but the higher
transfusion threshold was associated with more adverse
events. Based on these limited numbers of patients, it
seems premature to conclude that a low transfusion
threshold may be beneficial in all TBI patients; more
data are needed.
In a pilot trial involving 44 aneurysmal SAH patients
with high risk of cerebral vasospasm, Naidech and col-
leagues reported no significant difference in the prede-
fined safety endpoints when using a liberal transfusion
strategy to maintain Hb >11.5 g/dl compared with a
conservative approach (target Hb >10 g/dl) [38]. In a
post hoc analysis, however, patients in the lower Hb
group had more cortical infarctions, suggesting that
higher Hb thresholds may be needed to provide protectionfrom vasospasm-related infarction. In one retrospective
analysis of 205 consecutive patients with aneurysmal SAH,
there was a higher risk of thrombosis, pulmonary embol-
ism and poor outcome in patients receiving blood trans-
fusion [39]. This correlation persisted in multivariable
analysis: odds ratio of 2.4 (95% confidence interval = 1.2 to
4.6, P = 0.01) for thromboembolic event, and odds ratio of
5.0 (95% confidence interval = 1.9 to 12.8, P <0.01) for
poor outcome.
TBI and aneurysmal SAH are clearly distinct en-
tities and require specific studies to identify optimal
Hb levels. In both pathologies, however, the benefits
of red blood cell transfusion may only exceed the as-
sociated risks if physiologic triggers – for example,
brain tissue hypoxia or brain metabolic distress – in-
dicate that transfusion is required. In this context,
simultaneous occurrence of anemia and compromised
brain tissue oxygen tension (PbtO2), but not anemia
alone, was correlated with poor 1-month outcomes in
patients with TBI [40].
Preserving brain perfusion in sepsis
Brain dysfunction is frequent during sepsis and is associ-
ated with increased mortality and long-term cognitive
dysfunction. The pathophysiology is complex and poorly
understood [41], but decreased brain perfusion may be a
major determinant [42]. Some studies have shown lower
CBF in septic patients than in healthy volunteers, but
other factors, such as sedative agents or hypocapnia as-
sociated with hyperventilation, may also explain the CBF
reduction in such patients. Sepsis is also associated with
impaired CBF autoregulation, however, especially when
shock is present [42,43]. A low arterial carbon dioxide
tension may enhance or restore the regulation of brain
perfusion in septic patients, without significantly affect-
ing cerebral oxygen metabolism [44]. However, the im-
pact of hypocapnia in these patients needs to be studied
in larger cohorts. Brain dysfunction during sepsis also
occurs in hemodynamically stable patients and experi-
mental data have suggested that regional brain perfusion
can become inadequate because of microcirculatory al-
terations [45].
An optimal threshold of blood pressure (or any other
metric) to prevent brain hypoperfusion in septic patients
has not yet been identified. Novel monitoring tools will
hopefully help improve our understanding of CBF and
microvascular regulation and facilitate identification of
specific neuroprotective strategies to minimize secondary
ischemic brain injuries in this setting.
Hepatic encephalopathy
Etiological factors in hepatic encephalopathy relate largely
to increased circulating ammonia with changes in cel-
lular glutamine/glutamate levels, altered neurotransmitter
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glial and mitochondrial dysfunction [46]. Drugs to de-
crease arterial ammonia levels have not been shown to be
effective in acute liver failure but may have a role in
cirrhosis. The use of novel agents to increase skeletal me-
tabolism of ammonia has been shown to be effective in
animal models [47]. Ammonia levels may also be manipu-
lated by renal replacement therapies. Control of the in-
flammatory phenotype may also be relevant, with animal
studies showing that decreasing brain inflammation may
be beneficial. Clinical studies in acute liver failure suggest
that combined control of ammonia (with renal replace-
ment therapy), inflammatory phenotype, temperature and
hyponatremia may be beneficial [48,49]. The long-term ef-
fects of hepatic encephalopathy in patients with acute
liver failure have not been widely examined but those
who recover are largely neurologically intact. In those
individuals with cirrhosis, chronic encephalopathy can
be seen and may be difficult to distinguish from other
neurological syndromes. Liver transplantation largely re-
sults in resolution of encephalopathy.
Body temperature, brain temperature and neuroprotection
Brain temperature has been shown to exceed measured
core temperature by between 1 and 2°C in various types
of brain injury [50]. Numerous studies in patients with
acute brain injury have shown links between fever and
adverse outcome, regardless of the cause of fever [51].
Some studies have shown links between low-grade
hyperthermia (>37.5°C) and adverse outcomes [52]; how-
ever, evidence that treating fever improves outcomes is
still lacking.
Controlled lowering of core body temperature to miti-
gate secondary injuries (including reperfusion injury)
after acute brain injury has been widely studied. Multiple
animal studies have shown that therapeutic (induced)
hypothermia (TH) may mitigate ischemia–reperfusion
injury and reduce brain edema. Both mechanisms may
be present within the same patient, but the two pro-
cesses differ and, crucially, have different time frames
requiring fundamentally different approaches to treat-
ment. Ischemia–reperfusion involves mechanisms that
begin within minutes to hours after injury, and effects last
up to 72 hours after the initial ischemic insult (with the
important exception of apoptosis, which starts later and
may be more prolonged) [52,53]. Therefore, at least the-
oretically, ischemia–reperfusion requires rapid treat-
ment, ideally before or in the early stages of injury and
lasting up to 72 hours as an optimal time frame. In con-
trast, brain edema would require treatment for as long
as it persists, and thus treatment periods would be
highly variable.
Clinical studies attempting to translate the promising
animal TH data to the bedside have yielded variable andsometimes conflicting results. There is strong evidence
from studies in TBI, acute ischemic stroke with brain
edema and acute hepatic encephalopathy that use of TH
lowers ICP. However, reduced ICP does not necessarily
equate with improved outcome, and clinical results
have been variable. Most studies using TH for limited
durations in severe TBI have not found benefits for
neurological outcome, and studies involving TH for
limited periods according to a fixed protocol often re-
ported rebound increases in ICP when patients were
rewarmed. Better results have been reported from
studies using TH for more prolonged periods (4 to
5 days) [51]. A large European trial testing the use of TH to
control ICP (Current Controlled Trials ISRCTN34555414)
has been recently closed to recruitment, with no data
yet available on outcomes. An Australian–New Zealand
study (Clinical Trials NCT00987688) of very early
TH to improve outcome after severe TBI is currently
ongoing.
Hypothermia in acute ischemic stroke was initially
used to control malignant brain edema in patients with
large middle cerebral artery stroke [51]. More recently,
pilot studies have used hypothermia to mitigate ischemia–
reperfusion injury in patients with acute ischemic stroke
undergoing thrombolysis or mechanical thrombectomy.
Of note, these studies involved nonintubated and only
mildly sedated patients, and used TH strategies such as
skin counterwarming, magnesium drips and buspirone
administration to manage shivering. The results are prom-
ising but as yet inconclusive.
Following out-of-hospital cardiac arrest, recent data
suggest that very mild hypothermia (36°C) may be as pro-
tective as moderate hypothermia (33°C) [54], although this
remains a topic of debate [55]. Patients with post-traumatic
cardiac arrest have a grim prognosis. Surgeons often can-
not stop bleeding quickly enough to prevent irreversible
damage to the brain and other organs, even if the ori-
ginal injuries are technically reparable. Emergency pres-
ervation and resuscitation may represent a method for
preserving life during a period of no blood flow to allow
time for the surgeon to achieve hemostasis, followed by
delayed resuscitation using cardiopulmonary bypass.
Currently, the best approach to inducing emergency
preservation and resuscitation is an intra-aortic flush of
ice-cold saline to achieve a brain temperature of 10°C.
In animal models, this profound cooling has allowed
survival with good neurologic outcome after prolonged
hemorrhage leading to cardiac arrest [56] or rapid ex-
sanguination followed by 2 to 3 hours of circulatory arrest
[57]. A clinical safety and feasibility trial is underway in
the USA in patients with penetrating trauma leading to
cardiac arrest within 5 minutes of emergency department
arrival or in the emergency department (Clinical Trials
NCT01042015).
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Neurorepair strategies
In addition to neurological damage, acute brain injury
induces a series of neurorestorative events [58]. In some
cases, the central nervous system is able to remodel
itself following insults that impair tissue homeostasis.
Neurorestorative events include neurogenesis, gliogen-
esis, angiogenesis, synaptic plasticity and axonal sprout-
ing. These processes are stimulated by endogenous
growth-related factors and may continue for weeks to
months, facilitating functional and structural recovery.
Unfortunately, these restorative processes are largely in-
effective for the severity of damage usually encountered
in TBI or stroke. Accordingly, providing such injured tissue
with a milieu that enhances neuroregenerative processes
has become an important therapeutic target.
Mesenchymal stromal cells
Infusion of mesenchymal stromal cells (MSCs) can im-
prove structural and functional outcomes in different
brain injury models [59]. MSCs secrete growth and neuro-
trophic factors or induce their production by resident
brain cells, including microglia. The interaction between
MSCs and inflammatory microenvironments is crucial.
MSCs can reprogram the local microenvironment from
a detrimental function to a beneficial role, reducing
toxic events and promoting endogenous restorative pro-
cesses [60,61].
The protection induced by MSCs is extremely variable
across studies. In addition to methodological differences
between injury models and laboratories, heterogeneity in
MSC populations also contributes to disparate outcomes.
MSCs obtained from different sources (for example, bone
marrow versus umbilical cord blood versus amniotic fluid)
are characterized by different protective potency. Further-
more, MSCs obtained from similar sources but from dif-
ferent donors can display different effects [62]. To predict
in vivo potency, additional experimental work is needed to
identify the specific properties of each MSC subpopula-
tion, and to understand determinants of intrinsic hete-
rogeneity. Before translating MSC-based therapies to the
clinical environment, safety and consistency also need to
be confirmed.
Remote ischemic conditioning
Brief repeated cycles of peripheral vascular occlusion
and de-occlusion in dogs prior to induction of coronary
ischemia reduce myocardial infarct size [63]. This remote
ischemic preconditioning is presumed to induce humoral
factors that prevent reperfusion injury in several organs,
including the brain. Protection occurs through modifica-
tion of intracellular kinase activity, mitochondrial perme-
ability and the inflammatory response to reperfusion [64].
One potential means by which ischemic conditioning canbe achieved is by application of a standard blood pressure
cuff to the arm and alternating 5-minute cycles of inflation
and release [65].
Ischemic conditioning may be applied before (precondi-
tioning), during (perconditioning) or after (postcondition-
ing) a cerebral ischemic event. In patients, perconditioning
as an adjunct to treatment with intravenous alteplase was
associated with a reduction in tissue risk of infarction after
acute thrombotic stroke [66]. Preconditioning has also been
associated with prevention of recurrent stroke in patients
with intracranial arterial stenosis [67]. Nevertheless, several
questions remain unanswered: would remote ischemic
conditioning reduce infarct size if administered before
thrombolytic reperfusion of acute thrombotic stroke;
can repeated (daily for weeks to months) ischemic con-
ditioning improve long-term outcomes after cerebral
ischemia; and in what other settings could ischemic con-
ditioning reduce reperfusion injury and produce better
clinical outcomes?
Volatile anesthetic agents for neuroprotection
Volatile anesthetic agents may have neuroprotective prop-
erties. Pretreatment with isoflurane improved long-term
neurological outcomes after experimental hypoxic/ischemic
bran injury or focal brain ischemia [68] and post-treatment
provided neuroprotection in rats [69]. The inducible form
of nitric oxide synthase may mediate the tolerance to ische-
mia. Other factors that could be involved are the inhibition
of excitatory neurotransmission and regulation of intracel-
lular calcium responses during ischemia. Although attract-
ive for their potential benefit on ischemic damage, these
experiments have not been translated into clinical studies
because use of a volatile agent may also induce vasodilata-
tion, increasing CBF and, consequently, elevations in ICP.
In SAH patients, however, in whom an increase in CBF
may be beneficial, the availability of a pragmatic bedside
dispensing device and continuous ICP and regional CBF
monitoring has made the inhalation of isoflurane for neu-
roprotection in the ICU practical, and this approach has
been assessed in a small pilot study [70]. Nevertheless, at
this stage, the use of volatile agents remains unproven and
not ready for clinical implementation [71].
Metabolic therapy: alternative fuel for the injured human
brain
The brain can use alternative substrates beyond glucose,
including lactate, pyruvate and ketone bodies, particu-
larly in conditions of increased energy demand and lim-
ited glucose availability (for example, exercise, starvation,
hypoglycemia or hypoxia/ischemia). Preferential use of
lactate over glucose has been demonstrated in healthy
human subjects [72] and diabetic patients [73]. Sodium
lactate infusion has been shown to be neuroprotective in
several brain injury models, both in vitro and in vivo
Box 2. Approaches to optimize translation of
interventions from animal studies to clinical
neuroprotection using experimental medicine
approaches
1. Demonstration of existence, timing, and duration of target
pathophysiology affected by candidate intervention in human
disease (proof of mechanism).
2. Demonstration that the target molecule enters the brain in
patients, at levels needed to produce benefit (favorable
central nervous system pharmacokinetics).
3. Demonstration that the target molecule results in changes in
target pathophysiological process in human disease (proof of
concept).
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or sodium lactate) may prevent brain edema and eleva-
tions of ICP following TBI [78,79]. Solutions containing
lactate have favorable cerebral metabolic effects in patients
with TBI [78]. Acetyl-L-carnitine infusion may also exert
protective effects on the injured cells [80].
Overall, these data support the hypothesis that supple-
mentation of the injured human brain with alternate
energy fuels may be beneficial after acute brain injury
[81]. Although a large trial of prehospital hypertonic sa-
line infusions did not show beneficial effects on outcome
[26], administration of isotonic or hypertonic solutions
containing lactate, pyruvate or ketones may be a better
option for the treatment of brain edema and cerebral is-
chemia following acute brain injury by enhancing brain
energetics and, in turn, neurological recovery.
Sex hormones
In numerous models, early parenteral administration of
sex hormones has anti-apoptotic, anti-inflammatory and
anti-oxidant properties and can accelerate reparative
processes that prevent long-term sequelae [82]. One po-
tential long-term reparative action of estrogens relates to
their effects on sonic hedgehog, a signaling protein that
controls and directs differentiation of neural stem cells,
thus influencing brain repair by generating new neurons
whenever necessary. Estrogen-induced acceleration of
sonic hedgehog production may represent a potential
pathway for neuroregeneration and neuroprotection
[83]. Laboratory data have shown that the relevant effects
of sex hormones in neurological emergencies, such as
TBI, stroke and spinal cord injury, are neither cell-type
specific nor insult specific [84,85].
Several clinical trials of sex hormones in TBI have
recently been completed. The phase II RESCUE–TBI
study (Clinical Trials NCT00973674) evaluated the safety
and feasibility of administering a single dose of intraven-
ous conjugated estrogens (Premarin; Pfizer Inc., New
York, NY, USA) in patients with severe TBI, but no results
are yet available. The National Institutes of Health-
sponsored ProTECT III study evaluated the effects of
intravenous progesterone (started within 4 hours of injury
and given for a total of 96 hours) versus placebo in pa-
tients with moderate to severe TBI, but was stopped for
futility [86]. The SyNAPSe Trial, comparing intravenous
progesterone with placebo within 8 hours of severe TBI
for a total of 120 hours, completed enrollment but failed
to demonstrate a benefit [87]. There is therefore currently
no clinical evidence to support sex hormone usage in TBI.
Hyperoxia in neuroprotection
Oxygen is an essential substrate for the brain; however,
the safety margin between effective and toxic oxygen
doses is relatively narrow. Oxygen may be toxic to thelungs (for example, tracheobronchitis, absorption atelec-
tasis, hypoxic pulmonary vasoconstriction and hyperoxia-
induced lung injury), the circulation and the brain tissue
itself (seizures or lipid peroxidation) [88], and hyperoxia
has been associated with increased mortality in patients
with various acute neurological disease processes [24,89-91].
However, hyperoxia can increase PbtO2, restore mito-
chondrial redox potential, decrease ICP, restore aerobic
metabolism and improve pressure autoregulation [92-94].
Administering 100% oxygen at normal atmospheric pres-
sure (normobaric hyperoxia) is inexpensive, widely avail-
able and can be started promptly after TBI or stroke (for
example, by paramedics). Results in humans, however,
have been mixed [24,93,95-97]. There is probably a nar-
row effective dose, and benefit may be limited to at-risk
tissue. Moreover, treatment may only be effective in
specific subgroups of patients or may depend on the
metabolic state [97]. Furthermore, whether improve-
ments in brain metabolism translate into better outcome
is unclear [96].
Hyperbaric oxygen has been shown to reduce infarct
volume, blood–brain barrier disruption, edema and neu-
rologic deficits in animal models of ischemic brain injury
[98]. In experimental TBI, hyperbaric oxygen decreased
neuron injury and edema [99]. In a small group of severe
TBI patients, hyperbaric oxygen improved brain metabol-
ism and decreased ICP [100]. However, administering
hyperbaric oxygen can be clinically challenging, requiring
that patients are moved out of the ICU to the hyperbaric
oxygen chamber, an expensive facility available in only a
few centers. In a small study of 42 TBI patients, the com-
bination of hyperbaric and normobaric hyperoxia was as-
sociated with significant outcome benefits compared with
standard therapy [101]. These results need confirmation
in larger studies.
Box 3. Recommendations for clinical trial design from
the International Mission on Prognosis and Analysis of
randomized Controlled Trials in TBI study group
1. Inclusion criteria should be as broad as is compatible with
the current understanding of the mechanism of action of the
intervention being evaluated.
2. The statistical analysis should incorporate prespecified
covariate adjustment to mitigate the effects of heterogeneity.
3. The statistical analysis should use an ordinal approach, based on
either sliding dichotomy or proportional odds methodology.
Stocchetti et al. Critical Care  (2015) 19:186 Page 7 of 11PbtO2 monitoring is often used to optimize oxygenation
targets and evaluate the utility of therapeutic inter-
ventions. Decreases in PbtO2 are associated with chemical
markers of brain injury and with both mortality and un-
favorable outcome after TBI [102], with similar (but less
robust) associations in SAH. Addition of PbtO2-based
care to conventional ICP-based and CPP-based care
has been associated with improved outcomes after severe
TBI [103,104]. This issue has been evaluated in a multicen-
ter phase II clinical trial (Clinical Trials NCT00974259).
Preliminary results demonstrate the feasibility and safety of
PbtO2-based care and suggest a benefit to outcome, but
phase III trials are necessary to confirm these findings.Figure 1 Neuroprotective strategies in the ICU. To avoid further insults
intensive care management are to ensure adequate oxygen delivery and to
of high brain temperature. See text for details on reperfusion after ischemic
pressure (CPP) levels. ICP, intracranial pressure; MAP, mean arterial pressureLessons learned
Providing protection to the brain from different injuries
has proven to be an ambitious goal, with a long series of
clinical trial failures, especially for pharmacologic pro-
tection after TBI. In some instances, there may have
been flaws in the experimental methodology (for ex-
ample, relevance and quality of models, incomplete un-
derstanding of treatment mechanisms and inadequate
elucidation of brain pharmacokinetics of the drug used).
Many important methodological issues in animal studies
are not adequately addressed before clinical trials are
commenced (Box 1). It is often assumed that a disease
mechanism detected in an animal model is also present
in human disease, and that it has the same relevance,
timing and duration as seen in the model. It is also often
assumed that a candidate drug which is effective in
reducing a pathophysiological process in animal models
will have the same effect in humans. A careful analysis of
failed neuroprotection trials suggests that these assump-
tions are unsafe [105]. The comprehensive monitoring
of cerebral physiology and biochemistry commonly em-
ployed in critically ill patients with acute brain injury
(especially TBI and SAH) provides a valuable opportunity
to challenge some of these assumptions in preliminary
studies, or as part of early phase II trials, before proceeding
to more definitive studies (Box 2). Closer collaborations
between preclinical investigators and clinical counter-
parts will be key to improving methodologies in both
settings.to the brain (NMR image of a normal brain at the center), the goals of
avoid excessive oxygen consumption, as in epileptic crises and cases
stroke, optimal hemoglobin level, and desirable cerebral perfusion
; PaO2, arterial oxygen tension.
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have been sufficiently sensitive and there has been a
failure to adequately address the inherent heterogen-
eity of the patient populations [106]. The IMPACT
studies have addressed methodological issues of trial
design in TBI with an emphasis on dealing with the
population heterogeneity and increasing sensitivity of
outcome analysis [107] (Box 3). Although the IMPACT
project has resulted in substantial advances by addressing
problems related to prognostic heterogeneity, it did
not address heterogeneity related to mechanism. Early
mechanistic endpoints, which can serve as intermediate
outcome markers in TBI trials, are still lacking. It will be
impossible to mount a sufficient number of adequately
powered clinical trials to address all existing uncer-
tainties in the management of TBI. Alternative designs
should therefore be considered. Rather than dealing with
heterogeneity, we may be able to make use of it by
employing comparative effectiveness research approa-
ches [108].
Adaptive clinical trial design can reduce the risk of un-
informative failed trials resulting from studies based on
erroneous assumptions. Adaptive trials allow the pre-
planned modification of key clinical trial characteristics
during the trial implementation phase based upon new
information acquired within the trial itself and a set of
carefully simulated rules (for example, changing the
number of treatment arms, available dosing levels,
randomization ratios and inclusion/exclusion criteria).
The goal is to achieve statistical efficiency, improved
ethical balance and scientific validity [109,110]. Com-
pared with a traditional, fixed trial methodology, a well-
designed adaptive trial can increase the probability of
correctly identifying a truly effective therapy and can
hasten the identification of futility, allowing scarce re-
sources to be more rapidly directed towards the next
promising target or project [111].
Conclusion
Despite all the disappointments, there are many new
therapeutic possibilities still to be explored and tested.
Moreover, although the outcome benefits of specific
agents and interventions have not been demonstrated,
major advances in the clinical outcomes of our patients
have been made in recent decades by applying a package
of clinical measures, including meticulous monitoring
and careful prevention and limitation of secondary in-
sults in the early phases after injury (see Figure 1) [112].
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